Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Abstract Background Development of resistance to targeted therapies has tempered initial optimism that precision oncology would improve poor outcomes for cancer patients. Resistance mechanisms, however, can also confer new resistance-specific vulnerabilities, termed collateral sensitivities. Here we...

Full description

Bibliographic Details
Main Authors: Mareike Berlak, Elizabeth Tucker, Mathurin Dorel, Annika Winkler, Aleixandria McGearey, Elias Rodriguez-Fos, Barbara Martins da Costa, Karen Barker, Elicia Fyle, Elizabeth Calton, Selma Eising, Kim Ober, Deborah Hughes, Eleni Koutroumanidou, Paul Carter, Reda Stankunaite, Paula Proszek, Neha Jain, Carolina Rosswog, Heathcliff Dorado-Garcia, Jan Jasper Molenaar, Mike Hubank, Giuseppe Barone, John Anderson, Peter Lang, Hedwig Elisabeth Deubzer, Annette Künkele, Matthias Fischer, Angelika Eggert, Charlotte Kloft, Anton George Henssen, Michael Boettcher, Falk Hertwig, Nils Blüthgen, Louis Chesler, Johannes Hubertus Schulte
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Molecular Cancer
Subjects:
Neuroblastoma
CRISPR screening
ALK
Resistance
NF1
NRAS
Online Access:https://doi.org/10.1186/s12943-022-01583-z

Internet

https://doi.org/10.1186/s12943-022-01583-z

Similar Items